首页> 外文期刊>Leukemia Research Reports >Standard and variant Philadelphia translocation in a CML patient with different sensitivity to imatinib therapy
【24h】

Standard and variant Philadelphia translocation in a CML patient with different sensitivity to imatinib therapy

机译:对伊马替尼治疗敏感性不同的CML患者的标准和变异费城易位

获取原文
           

摘要

Most chronic myeloid leukemia (CML) patients show the Philadelphia chromosome (Ph) arising from the reciprocal t(9;22), but 5–10% present variants of this translocation involving different breakpoints besides 9q34 and 22q11. We report the non simultaneous occurrence of two different types of Ph translocation in a CML patient: a t(9;22)(q34;q11) standard and a three-way variant t(9;11;22)(q34;p15;q11). Bone marrow cells with standard translocation did not have BCR/ABL kinase domain (KD) mutations and were sensitive to imatinib therapy. In contrast, bone marrow cells with the variant translocation showed two BCR/ABL KD mutations and were resistant to imatinib, thus inducing transformation to the blast phase and karyotype evolution.
机译:大多数慢性粒细胞白血病(CML)患者显示出倒数t(9; 22)引起的费城染色体(Ph),但是5-10%的患者出现了这种易位的变异,除了9q34和22q11以外还涉及不同的断点。我们报告了在CML患者中同时发生两种不同类型的Ph移位的情况:at(9; 22)(q34; q11)标准和三向变体t(9; 11; 22)(q34; p15; q11 )。具有标准易位的骨髓细胞没有BCR / ABL激酶结构域(KD)突变,并且对伊马替尼治疗敏感。相反,具有变异易位的骨髓细胞显示出两个BCR / ABL KD突变,并且对伊马替尼具有抗性,从而诱导了向胚芽期的转化和核型的进化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号